Suppr超能文献

巴西复发麻风病患者分枝杆菌分离株的药物和多种药物耐药性。

Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients.

机构信息

Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.

出版信息

J Clin Microbiol. 2012 Jun;50(6):1912-7. doi: 10.1128/JCM.06561-11. Epub 2012 Apr 11.

Abstract

Skin biopsy samples from 145 relapse leprosy cases and from five different regions in Brazil were submitted for sequence analysis of part of the genes associated with Mycobacterium leprae drug resistance. Single nucleotide polymorphisms (SNPs) in these genes were observed in M. leprae from 4 out of 92 cases with positive amplification (4.3%) and included a case with a mutation in rpoB only, another sample with SNPs in both folP1 and rpoB, and two cases showing mutations in folP1, rpoB, and gyrA, suggesting the existence of multidrug resistance (MDR). The nature of the mutations was as reported in earlier studies, being CCC to CGC in codon 55 in folP (Pro to Arg), while in the case of rpoB, all mutations occurred at codon 531, with two being a transition of TCG to ATG (Ser to Met), one TCG to TTC (Ser to Phe), and one TCG to TTG (Ser to Leu). The two cases with mutations in gyrA changed from GCA to GTA (Ala to Val) in codon 91. The median time from cure to relapse diagnosis was 9.45 years but was significantly shorter in patients with mutations (3.26 years; P = 0.0038). More than 70% of the relapses were multibacillary, including three of the mutation-carrying cases; one MDR relapse patient was paucibacillary.

摘要

从巴西五个不同地区的 145 例复发麻风病例中采集皮肤活检样本,用于对与麻风分枝杆菌耐药性相关的部分基因进行序列分析。在 92 例阳性扩增病例中的 4 例(4.3%)观察到这些基因中的单核苷酸多态性(SNP),包括仅 rpoB 突变的病例、folP1 和 rpoB 中均存在 SNP 的另一个样本,以及两个 folP1、rpoB 和 gyrA 均存在突变的病例,提示存在多药耐药(MDR)。突变的性质与早期研究中报道的相同,folP 中的密码子 55 从 CCC 突变为 CGC(Pro 突变为 Arg),而 rpoB 中的所有突变均发生在密码子 531 处,其中两个突变为 TCG 突变为 ATG(Ser 突变为 Met),一个突变为 TCG 突变为 TTC(Ser 突变为 Phe),一个突变为 TCG 突变为 TTG(Ser 突变为 Leu)。gyrA 中发生突变的两个病例,其密码子 91 从 GCA 突变为 GTA(Ala 突变为 Val)。从治愈到复发诊断的中位时间为 9.45 年,但突变患者的时间明显缩短(3.26 年;P = 0.0038)。超过 70%的复发为多菌型,包括 3 例携带突变的病例;1 例 MDR 复发患者为少菌型。

相似文献

1
Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients.
J Clin Microbiol. 2012 Jun;50(6):1912-7. doi: 10.1128/JCM.06561-11. Epub 2012 Apr 11.
2
Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country.
PLoS Negl Trop Dis. 2016 Oct 5;10(10):e0005041. doi: 10.1371/journal.pntd.0005041. eCollection 2016 Oct.
5
Drug resistance in Mycobacterium leprae from patients with leprosy in China.
Clin Exp Dermatol. 2015 Dec;40(8):908-11. doi: 10.1111/ced.12665. Epub 2015 May 19.
7
A report of rifampin-resistant leprosy from northern and eastern India: identification and in silico analysis of molecular interactions.
Med Microbiol Immunol. 2015 Apr;204(2):193-203. doi: 10.1007/s00430-014-0354-1. Epub 2014 Sep 9.
8
Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients.
J Glob Antimicrob Resist. 2018 Mar;12:214-219. doi: 10.1016/j.jgar.2017.10.010. Epub 2017 Oct 31.
9
Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.
Clin Microbiol Infect. 2018 Dec;24(12):1305-1310. doi: 10.1016/j.cmi.2018.02.022. Epub 2018 Mar 1.
10
Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae.
Sci Rep. 2018 Mar 22;8(1):5016. doi: 10.1038/s41598-018-23423-1.

引用本文的文献

2
Computational investigation of the global prevalence of multidrug resistant : A systematic review and meta-analysis.
J Clin Tuberc Other Mycobact Dis. 2024 Nov 7;37:100495. doi: 10.1016/j.jctube.2024.100495. eCollection 2024 Dec.
5
Gene expression patterns associated with multidrug therapy in multibacillary leprosy.
Front Cell Infect Microbiol. 2022 Jul 22;12:917282. doi: 10.3389/fcimb.2022.917282. eCollection 2022.
6
Antimicrobial Resistance among Leprosy Patients in Brazil: Real-World Data Based on the National Surveillance Plan.
Antimicrob Agents Chemother. 2022 May 17;66(5):e0217021. doi: 10.1128/aac.02170-21. Epub 2022 Apr 18.
7
Drug Resistance in in the Context of Zero Leprosy.
Indian Dermatol Online J. 2021 Nov 22;12(6):791-795. doi: 10.4103/idoj.idoj_599_21. eCollection 2021 Nov-Dec.
8
Intein Inhibitors as Novel Antimicrobials: Protein Splicing in Human Pathogens, Screening Methods, and Off-Target Considerations.
Front Mol Biosci. 2021 Oct 7;8:752824. doi: 10.3389/fmolb.2021.752824. eCollection 2021.
9
Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?
Pharmaceutics. 2020 Dec 11;12(12):1202. doi: 10.3390/pharmaceutics12121202.

本文引用的文献

2
Molecular drug susceptibility testing and genotyping of Mycobacterium leprae strains from South America.
Antimicrob Agents Chemother. 2011 Jun;55(6):2971-3. doi: 10.1128/AAC.00201-11. Epub 2011 Mar 28.
3
Leprosy therapy, past and present: can we hope to eliminate it?
Indian J Dermatol. 2010 Oct;55(4):316-24. doi: 10.4103/0019-5154.74528.
7
[Retrospective study on leprosy relapse in the State of Espírito Santo].
Rev Soc Bras Med Trop. 2009 Jul-Aug;42(4):420-4. doi: 10.1590/s0037-86822009000400012.
9
10
Relapse in leprosy.
Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):126-35. doi: 10.4103/0378-6323.48656.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验